Get the Stockscreener App
1.48
4.96%
0.07
Theratechnologies Inc stock is traded at $1.48, with a volume of 536.77K.
It is up +4.96% in the last 24 hours and down -7.50% over the past month.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
536.77K
Relative Volume:
0.58
Market Cap:
$68.05M
Revenue:
$84.32M
Net Income/Loss:
$-3.16M
P/E Ratio:
-29.60
EPS:
-0.05
Net Cash Flow:
$-4.50M
1W Performance:
-1.33%
1M Performance:
-7.50%
6M Performance:
+23.08%
1Y Performance:
-1.33%
1-Day Range:
$1.38
$1.54
1-Week Range:
$1.31
$1.54
52-Week Range:
$1.08
$2.18
Theratechnologies Inc Stock (THTX) Company Profile
Compare THTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THTX
Theratechnologies Inc
|
1.48 | 68.05M | 84.32M | -3.16M | -4.50M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Theratechnologies Inc Stock (THTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Theratechnologies Inc Stock (THTX) Latest News
Theratechnologies Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update - couriernews.com
Theratechnologies Q1 Earnings: CEO and Executive Team to Reveal Latest Financial Performance - Stock Titan
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Drops By 13.6% - Defense World
AIGH Capital Management LLC Trims Holdings in Theratechnologies Inc. (NASDAQ:THTX) - MarketBeat
Virtu Financial LLC Invests $40,000 in Theratechnologies Inc. (NASDAQ:THTX) - Defense World
Theratechnologies Gains FDA Approval for New Tesamorelin Formulation - TipRanks
Theratechnologies rises after FDA label expansion for best seller Egrifta - MSN
Theratechnologies stock rises on FDA label expansion (THTX) - Seeking Alpha
Theratechnologies Receives FDA Approval for EGRIFTA WR - Contract Pharma
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday - MarketScreener
New Egrifta formulation picks up US FDA nod - The Pharma Letter
TSX futures flat as markets await clarity on tariffs - MarketScreener
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar - TradingView
FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy - ContagionLive
FDA approves new tesamorelin formulation by Theratechnologies - Investing.com Australia
Theratechnologies Gains FDA Nod for Enhanced HIV Treatment - TipRanks
FDA approves new tesamorelin formulation by Theratechnologies By Investing.com - Investing.com South Africa
Theratechnologies Receives FDA Approval for EGRIFTA WR™ - GlobeNewswire
Theratechnologies Shares Rise on FDA Approval for HIV-Induced Stomach Fat Treatment - MarketWatch
Theratechnologies announces FDA approval of sBLA for F8 formulation of tesamorel - TipRanks
Theratechnologies Receives FDA Approval For EGRIFTA WR (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy - Marketscreener.com
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess - Bluefield Daily Telegraph
Major FDA Win: New Weekly HIV Drug Cuts Treatment Burden by 85% - Stock Titan
Theratechnologies Inc. - Baystreet.ca
Stocks In Play: Theratechnologies Inc. - Barchart
Theratechnologies CROI Presentation Highlights Limitations - GlobeNewswire
Theratechnologies Reports Encouraging Results From PROMISE-US Trial Of Ibalizumab - Nasdaq
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV - The Manila Times
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of - The Bakersfield Californian
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI - GlobeNewswire
Theratechnologies Presents Encouraging Virologic - GlobeNewswire
Theratechnologies Inc. to Host Earnings Call - ACCESS Newswire
Theratechnologies, Inc. to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for THTX FY2027 Earnings - Defense World
FY2025 EPS Estimates for TSE:TH Reduced by Leede Financial - MarketBeat
Theratechnologies (NASDAQ:THTX) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Leede Financial Brokers Reduce Earnings Estimates for TSE:TH - Defense World
Theratechnologies (NASDAQ:THTX) Issues Earnings Results - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 212.7% in February - Defense World
Research Analysts Set Expectations for THTX FY2025 Earnings - Defense World
Theratechnologies’ Earnings Call: Growth Amid Challenges - TipRanks
What is Leede Financial's Estimate for THTX FY2025 Earnings? - MarketBeat
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... - Yahoo Finance
Theratechnologies Reports Strong Fiscal 2024 Performance - TipRanks
Theratechnologies reports Q4 revenue $25M vs $23.45M last year - TipRanks
Theratechnologies: Fiscal Q4 Earnings Snapshot - mySA
Theratechnologies Inc reports results for the quarter ended November 30Earnings Summary - TradingView
Earnings call transcript: Theratechnologies Q4 2024 sees growth amid strategic shifts - Investing.com UK
Theratechnologies Inc Stock (THTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):